These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37274644)

  • 41. Anesthesia and myasthenia gravis.
    Blichfeldt-Lauridsen L; Hansen BD
    Acta Anaesthesiol Scand; 2012 Jan; 56(1):17-22. PubMed ID: 22091897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis.
    Li M; Ge F; Guo R; Ruan Z; Gao Y; Niu C; Lin H; Zhao Z; Zhou Y; Li Z; Chang T
    Ther Adv Neurol Disord; 2019; 12():1756286419876521. PubMed ID: 35173803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myasthenia gravis: subgroup classification and therapeutic strategies.
    Gilhus NE; Verschuuren JJ
    Lancet Neurol; 2015 Oct; 14(10):1023-36. PubMed ID: 26376969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Isolated laryngeal myasthenia gravis for 26 years.
    Renard D; Hedayat A; Gagnard C
    Neuromuscul Disord; 2015 Feb; 25(2):153-4. PubMed ID: 25454167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis.
    Chirapapaisan N; Tanormrod S; Chuenkongkaew W
    Asian Pac J Allergy Immunol; 2007 Mar; 25(1):13-6. PubMed ID: 17891917
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A retrospective observational study on characteristics, treatment patterns, and healthcare resource use of patients with myasthenia gravis in England.
    van Enkhuizen J; Binns J; Betts A; Hosnijeh FS; Alexander M; McCormack M; Jacob S
    Ther Adv Neurol Disord; 2024; 17():17562864241237495. PubMed ID: 38634003
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pembrolizumab-induced myasthenia gravis: A fatal case report.
    March KL; Samarin MJ; Sodhi A; Owens RE
    J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study.
    Remijn-Nelissen L; Verschuuren JJGM; Tannemaat MR
    Neuromuscul Disord; 2022 Oct; 32(10):790-799. PubMed ID: 36184373
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tolosa-Hunt syndrome with general myasthenia gravis involvement.
    Li L; Wang Z; Lu MO
    J Integr Neurosci; 2020 Jun; 19(2):355-357. PubMed ID: 32706200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2003; (2):CD002277. PubMed ID: 12804431
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults With Generalized Myasthenia Gravis in the United States.
    Phillips G; Abreu C; Goyal A; Li Y; Whangbo A; Gelinas D; Brauer E; Bhattacharya S
    Front Neurol; 2021; 12():809999. PubMed ID: 35115997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient-reportedimpact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG).
    Berrih-Aknin S; Claeys KG; Law N; Mantegazza R; Murai H; Saccà F; Dewilde S; Janssen MF; Bagshaw E; Kousoulakou H; Larkin M; Beauchamp J; Leighton T; Paci S
    BMJ Open; 2021 Jul; 11(7):e048198. PubMed ID: 34285010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug Use Patterns in Myasthenia Gravis: A Real-World Population-Based Cohort Study in Italy.
    Finocchietti M; Crescioli G; Paoletti O; Brunori P; Sciancalepore F; Tuccori M; Addis A; Vannacci A; Lombardi N; Kirchmayer U; The Caesar Study Group
    J Clin Med; 2024 Jun; 13(11):. PubMed ID: 38893023
    [No Abstract]   [Full Text] [Related]  

  • 54. Medical treatment options for ocular myasthenia gravis.
    Antonio-Santos AA; Eggenberger ER
    Curr Opin Ophthalmol; 2008 Nov; 19(6):468-78. PubMed ID: 18854691
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence and risk factors of myasthenia gravis recurrence post-thymectomy.
    Alqarni F; Almalki D; Aljohani Z; Ali A; AlSaleem A; Alotaibi N; Odeh S; Dalbhi SA
    Neurosciences (Riyadh); 2021 Jan; 26(1):4-14. PubMed ID: 33530037
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample.
    Xin H; Harris LA; Aban IB; Cutter G
    J Clin Neurol; 2019 Jul; 15(3):376-385. PubMed ID: 31286711
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidemiology of myasthenia gravis in the province of Ourense (Galicia, Spain).
    García Estévez DA; López Díaz LM; Pardo Parrado M; Pérez Lorenzo G; Sabbagh Casado NA; Ozaita Arteche G; Rodríguez Gómez D
    Neurologia (Engl Ed); 2023 Mar; 38(2):75-81. PubMed ID: 35249845
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Myasthenia Gravis and Its Aeromedical Implications.
    Jagathesan T; O'Brien MD
    Aerosp Med Hum Perform; 2017 Jan; 88(1):30-33. PubMed ID: 28061919
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Myasthenia gravis and hyperthyroidism: two cases].
    Trabelsi L; Charfi N; Triki Ch; Mnif M; Rekik N; Mhiri Ch; Abid M
    Ann Endocrinol (Paris); 2006 Jun; 67(3):265-9. PubMed ID: 16840920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.